Hemophilia Market

Hemophilia Market Size (2023 to 2028)

The global hemophilia market is estimated to grow at a CAGR of 6.12% from 2023 to 2028. The market size is expected to value USD 20.9 billion by 2028 from USD 15.53 billion in 2023.

Hemophilia is a genetic bleeding disorder in which the blood clot improperly. This results in spontaneous bleeding as well as bleeding after injuries or surgery. Internal bleeding may occur anywhere in the body, and bleeding into joints is normal. Therefore, it can be identified only after a person has an abnormal bleeding issue. A blood test can also determine it. Blood contains different types of proteins called clotting factors that can help to stop bleeding. Hemophilia is caused mainly due to mutations in either the factor VIII or factor IX genes on the X chromosome. Hemophilia is of 3 types, hemophilia C, hemophilia B, and hemophilia A. According to WFH (World Federation of Hemophilia), hemophilia is more recorded in males, and approximately 1 in 5,000 newborns suffer from type A. This is one of the rare genetic bleeding disorders that affected around 440,000 people worldwide in 2018.

Impact of COVID-19 on the global hemophilia market:

The outbreak of the COVID-19 pandemic is expected to have an impact on the hemophilia market. People with chronic medical conditions, such as hemophilia, must take extra precautions to reduce the risk of contracting COVID-19. In addition, people with hemophilia are more susceptible to infectious diseases and hence have a higher risk of contracting coronavirus. Several organizations, hospitals, and hematologists are working to manage the COVID-19 public health issue. For instance, in response to the coronavirus outbreak, the American Society of Haematology established a forum to exchange useful, precise, and up-to-date information to help hematologists. As a result, such approaches are predicted to assist in market recovery following the COVID-19 outbreak.

MARKET DRIVERS:

The growing patient population suffering from hemophilia, rising hemophilia among pediatrics, and the development of hemophilia treatment procedures are expected to drive the global hemophilia market.

According to the World Federation of Hemophilia global report in 2021, there were 209,615 people diagnosed with hemophilia, including 165,380 Hemophilia A patients, 33,076 Hemophilia B patients, and 11,159 Hemophilia type unknown patients worldwide. The significance of hemophilia is steadily rising among pediatrics. According to the World Federation of Haemophilia (WFH), hemophilia is expected to affect one out of every 10,000 births. Pediatrics suffering from hemophilia must lack enough clotting factors in their blood as they cannot stop bleeding, and they use specific hemophilia medications to prevent excessive bleeding.

In addition, the expansion of hemostats for wound healing and advancements in pharmaceutical drug delivery, rising diagnostic screening, increasing government investments, and changing lifestyles are expected to favor the growth rate of the hemophilia market. Rising healthcare expenditure, launching numerous campaigns and programs to generate awareness about early diagnosis, Y-O-Y growth in medical tourism, and initiatives, mergers, and acquisitions among the major players, increasing R&D efforts are further projected to accelerate the development of the hemophilia market. The increasing diagnosis rate and the growing use of prophylactic treatment for hemophilia are lucrative growth opportunities for the market.

MARKET RESTRAINTS:

The high cost of the treatment, lack of awareness regarding hemophilia, effects of plasma-derived products, and insufficient medicine for hemophilia are expected to hinder the growth of the hemophilia market worldwide. In addition, the lack of healthcare infrastructure in developing countries and lack of skilled professionals, and strict government regulations are other significant restraints to the hemophilia market growth.

REPORT COVERAGE:

This research report on the global hemophilia market has been segmented and sub-segmented based on type, treatment, therapy, end-user, and region.

Hemophilia Market - By Type:

• Hemophilia A
• Hemophilia B
• Hemophilia C

Based on type, the hemophilia A segment led the market in 2022. Hemophilia A is a common severe bleeding disorder. Nearly 60 percent of people suffer from this type of disease. Most products and treatments are available for Hemophilia A.

Hemophilia Market - By Treatment:

• On-Demand
• Prophylactic

Based on the treatment, the prophylactic segment accounted for a significant share of the global hemophilia market in 2022. Prophylaxis is a general method of clotting factor and is widely used in patients with severe hemophilia. The time taken for this treatment depends on the severity of the patients. Prophylaxis treatment is projected to reduce productivity loss with better quality-of-life outcomes.

Hemophilia Market - By Therapy:

• Replacement Therapy
• Immune Tolerance Induction (ITI) Therapy
• Gene Therapy

Based on the therapy, the gene therapy segment occupied the leading share of the global hemophilia market in 2022 due to the robust Research and Development in the respective field and advanced treatment options.  For example, FLT180ais, a gene therapy developed by A Phase 1 clinical trial, is now recruiting patients with hemophilia B in the U.K. Increasing R&D investments, identifying the defective DNA bases, and new drug launch in replacement therapy is estimated to drive the segment's growth. Replacement therapy, which provides the insufficient coagulation factor, has been the primary prophylactically treatment for bleeding.

Hemophilia Market – By End-User:

• Hospitals
• Clinics
• Hemophilia Treatment Centers

Based on the end-user, the hospital segment dominated the hemophilia market in 2022. This is due to the availability of certified skilled hematologists, the importance of delivering high-quality care plans, and their improved efficiency. In addition, the availability of advanced therapies in hospitals helps treat bleeding disorders. It provides minimum-cost treatment procedures that help both patients and insurance people equally. Growing hospital admissions with such generic bleeding disorders and demand for advanced treatments are projected to fuel the adoption of the product in these facilities.

Hemophilia Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America accounted for a significant share of the global hemophilia market in 2022. This is due to therapeutic advances in hemophilia, the increasing prevalence of hemophilia, raising awareness about technologically advanced products, and the presence of a vast patient population. According to the World Federation of Hemophilia (WFH), in 2018, around 17,758 individuals were diagnosed with hemophilia in the U.S. Hemophilia Federation of America (HFA) organization, which commonly delivers continuous treatment for patients by supporting specific co-pay initiatives.

The Asia Pacific market is expected to have the second-highest share due to increasing awareness and improved healthcare infrastructure. India and China are expected to witness significant growth due to a rise in per capita healthcare expenditure and improved healthcare infrastructure in these regions. With a rapidly growing population, minimal government regulations, increasing prevalence of hemophilia, and supportive government initiatives, the hemophilia treatment market in China is expected to expand rapidly during the forecast period.

Europe is expected to have a moderate share due to the increasing usage of technologically advanced devices for treating disorders such as hemophilia. Factors include the development of healthcare infrastructure and rising government initiatives, well-established healthcare facilities, recent technological advancements, and a rise in demand for early diagnosis of hemophilia. For example, the European Commission granted Novo Nordisk marketing approval for 'Esperoct' in Europe in June 2019.  Esperoct is used to treat hemophilia in adolescents and adults.

TOP COMPANIES IN THIS MARKET:

Baxter Healthcare Corporation, Biogen, Sanofi, Shire (Baxalta), CSL Behring, Bayer AG, Ferring Pharmaceuticals, Biomarin Phamaceutical Inc., Spark Therapeutics Inc., F. HOFFMAN LA ROCHE, Pfizer, Inc., Sanofi, Genentech, Inc., Novo Nordisk, GlaxoSmithKline Plc, and Bristol-Myers Squibb are some of the noteworthy players operating in the global hemophilia market profiled in this report.

RECENT MARKET DEVELOPMENTS:

• In December 2020, Takeda Pharmaceutical Company Limited announced that myPKFiT for ADYNOVATE, web-based software and mobile application, is the first and only pharmacokinetic (PK)-dosing software approved by the U.S. FDA for hemophilia A patients.
• In January 2022, Freeline Therapeutics Holdings plc announced to begin dosing of the second cohort in its Phase 1/2 B-LIEVE dose confirmation trial of FLT180a in people suffering from hemophilia B.